EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ZYUS Life Sciences's enterprise value is C$76.22 Mil.
ZYUS Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was C$-39.53 Mil. Therefore, ZYUS Life Sciences's EV-to-EBITDA for today is -1.93.
The historical rank and industry rank for ZYUS Life Sciences's EV-to-EBITDA or its related term are showing as below:
TSXV:ZYUS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -11.11 Med: -2.41 Max: -1.68
Current: -1.93
During the past 3 years, the highest EV-to-EBITDA of ZYUS Life Sciences was -1.68. The lowest was -11.11. And the median was -2.41.
TSXV:ZYUS's EV-to-EBITDA is ranked worse than 100% of 715
companies
in the Drug Manufacturers industry
Industry Median: 14.42
vs TSXV:ZYUS: -1.93
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
ZYUS Life Sciences EV-to-EBITDA Historical Data
The historical data trend for ZYUS Life Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ZYUS Life Sciences's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ZYUS Life Sciences's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ZYUS Life Sciences's EV-to-EBITDA falls into.
ZYUS Life Sciences's current Enterprise Value is C$76.22 Mil.
ZYUS Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-39.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZYUS Life Sciences (TSXV:ZYUS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
ZYUS Life Sciences's PE Ratio for today is calculated as:
ZYUS Life Sciences's share price for today is C$1.02.
ZYUS Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.817.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of ZYUS Life Sciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
ZYUS Life Sciences (TSXV:ZYUS) Business Description
ZYUS Life Sciences Corp is a next-generation life sciences company engaged in scientific research and development in phyto-therapeutics, including cannabinoid and protein-based formulations. It is committed to delivering high-quality standardized therapeutic formulations that comply with Good Manufacturing Practices (GMP) to provide targeted relief for patients in Canada and globally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSXV:ZYUS has been successfully added to your 